AMArthur Morley-Bunker

Arthur Morley-Bunker

*This is an algorithmically generated author record based on publicly available information.

Arthur Morley-Bunker has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • John F. Pearson

    Biostatistics and Computational Biology Unit, Department of Pathology and Biomedical Science, University of Otago, Christchurch, Christchurch, New Zealand

    3 shared publications
  • Logan C. Walker

    Department of Pathology & Molecular Medicine, University of Otago, Christchurch, Christchurch, New Zealand

    2 shared publications
  • Margaret Jane Currie

    Mackenzie Cancer Research Group Department of Pathology & Molecular Medicine University of Otago Christchurch Christchurch New Zealand

    2 shared publications
  • Allison L. Miller

    Department of Pathology and Biomedical Science, and Carney Centre for Pharmacogenomics, University of Otago, Christchurch, Christchurch, New Zealand

    1 shared publication
  • Anna P. Pilbrow

    Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch 8014, New Zealand

    1 shared publication
  • Brooke Beardsley

    Anatomical Pathology, Canterbury Health Laboratories, Te Whatu Ora–Health New Zealand Waitaha Canterbury, Christchurch, New Zealand

    1 shared publication

Latest Publications

  • Open Access

    Detection of Human Cytomegalovirus lncRNA4.9 in Breast Tumor Tissue Using RNA In Situ Hybridization

    by Arthur Morley-Bunker, Georgia Turner, Brooke Beardsley, Helen Morrin, John Pearson, Logan C. Walker, Margaret Currie

    Human cytomegalovirus (HCMV) has been linked to tumor progression in several cancers, but its role in breast cancer remains uncertain. This study investigated HCMV long non-coding RNA4.9 ( lncRNA4.9 ) in three breast cancer subtypes (ER+/PR+, n =25; HER2-positive n =24; triple-negative, n =26) and normal breast tissue ( n =5) using RNAscope. Serum HCMV IgG and IgM levels were measured, and immunohistochemistry was used to assess the pan-macrophage marker CD68 in breast tissue. HCMV IgG seropositivity was more common in ER+ patients, while IgM positivity was more frequent in HER2-positive and triple-negative cases. HCMV lncRNA4.9 signals were detected in over half of tumor samples, localizing to invasive tumor cells, stromal cells, adipose tissue, and ductal carcinoma in situ (DCIS). Although detection rates did not differ significantly between breast cancer subtypes, triple-negative tumors exhibited mid- to high-level lncRNA4.9 expression. Immunohistochemical analysis demonstrated CD68+ cells present in most tumors and were more abundant in HCMV lncRNA4.9 -positive samples. These cells co-localized with lncRNA4.9 -positive cells at invasive margins, while in associated foci of DCIS, CD68+ cells were present in surrounding stroma. This study provides the first demonstration of HCMV lncRNA4.9 in breast tissue and supports HCMV’s potential role in the biology of a subset of breast cancers.

  • Open Access

    Novel and Annotated Long Noncoding RNAs Associated with Ischemia in the Human Heart

    by Zoe Ward, Sebastian Schmeier, Louis Saddic, Martin I. Sigurdsson, Vicky A. Cameron, John Pearson, Allison Miller, Arthur Morley-Bunker, Josh Gorham, Jonathan G. Seidman, et al.

    Background: Long noncoding RNAs (lncRNAs) have been implicated in the pathogenesis of cardiovascular diseases. We aimed to identify novel lncRNAs associated with the early response to ischemia in the heart. Methods and Results: RNA sequencing data gathered from 81 paired left ventricle samples from patients undergoing cardiopulmonary bypass was collected before and after a period of ischemia. Novel lncRNAs were validated with Oxford Nanopore Technologies long-read sequencing. Gene modules associated with an early ischemic response were identified and the subcellular location of selected lncRNAs was determined with RNAscope. A total of 2446 mRNAs, 270 annotated lncRNAs and one novel lncRNA differed in response to ischemia (adjusted p < 0.001, absolute fold change >1.2). The novel lncRNA belonged to a gene module of highly correlated genes that also included 39 annotated lncRNAs. This module associated with ischemia (Pearson correlation coefficient = −0.69, p = 1 × 10−23) and activation of cell death pathways (p < 6 × 10−9). A further nine novel cardiac lncRNAs were identified, of which, one overlapped five cis-eQTL eSNPs for the gene RWD Domain-Containing Sumoylation Enhancer (RWDD3) and was itself correlated with RWDD3 expression (Pearson correlation coefficient −0.2, p = 0.002). Conclusion: We have identified 10 novel lncRNAs, one of which was associated with myocardial ischemia and may have potential as a novel therapeutic target or early marker for myocardial dysfunction.


  • Open Access

    RNAscope compatibility with image analysis platforms for the quantification of tissue-based colorectal cancer biomarkers in archival formalin-fixed paraffin-embedded tissue

    by Arthur E. Morley-Bunker, George A.R. Wiggins, Margaret J. Currie, Helen R. Morrin, Martin R. Whitehead, Tim Eglinton, John Pearson, Logan C. Walker